Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804472 | 0.85 | PROKR1 (0.35) | PROKR1GFERTACR3MGLLKMT2A | |
| SCHEMBL2943001 | 0.84 | MEN1 (0.39) | PROKR1MGLLKMT2AMEN1 | |
| SCHEMBL1802453 | 0.82 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL2939777 | 0.82 | MAPT (0.43) | — | |
| SCHEMBL2943359 | 0.81 | HPGD (0.41) | KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL2943345 | 0.81 | MEN1 (0.40) | MGLLKMT2AMEN1ALDH1A1 | |
| SCHEMBL2942901 | 0.81 | CHRNA4 (0.39) | KMT2AALDH1A1HTT | |
| SCHEMBL2942484 | 0.80 | SMN1; SMN2 (0.41) | MGLLKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL2936852 | 0.79 | HRH3 (0.44) | MGLL | |
| SCHEMBL2942272 | 0.78 | GAA (0.40) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | PROKR1 322/4885GFER 4268/4885TACR3 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.